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Summary 
Exogenous recombinant human thioredoxin (fiKX,  i>500 nM),  a dithiol reductase enzyme, 
inhibited the expression of human immunodeficiency virus (HIV) 1Bag in human macrophages 
(Me) by 71%  (range, 26-100%),  as evaluated by p24 antigen production and the integration 
of provirus at 14 d after infection. The stoichiometric reducing agent N-acetylcysteine (NAC) 
also inhibited HIV production, but to a lesser degree, and only at 30,000-fold higher concentrations. 
Exogenous ffRX is cleaved by M,  to generate the inflammatory cytokine, eosinophil cyto- 
toxicity-enhancing factor (ECEF).  In contrast to ffRX,  rECEF (concentrations from 50 pM 
to 2 gM) enhanced the production of HIV by 67%  (range, 33-92%).  Thus,  whereas TRX 
is a potent inhibitor of the expression of HIV in human Me, cleavage of TRX to ECEF creates 
a mediator with the opposite effect.  TRX also inhibited the expression of integrated provirus 
in the chronically infected OM 10.1 cell line, showing that it can act at a step subsequent to 
viral infection and integration. 
A  an intracellular dithiol reductase enzyme, thioredoxin 
(TRX) (13-14 kD) is thought to play a role in a number 
of oxidation reduction-dependent biochemical pathways (1). 
Human monocytes, lymphocytes, and other cell types also 
secrete TRX or related molecules (2-5) or display these spe- 
cies on the cell surface (4,  6).  The extracellular TRX and 
related species exhibit cytokine-like activities, including the 
induction of IL-2 receptors on T-lymphocyte cell lines (7) 
and the enhancement of eosinophil cytotoxic function (4, 8, 
9).  With  respect to eosinophil function,  the most potent 
stimulus is a TRX species truncated at the COOH terminus 
(eosinophil cytotoxicity-enhancing factor [ECEF],  10 kD), 
that is devoid of dithiol reductase enzymatic activity (4, 8, 9). 
In many cell types, the expression of mature HIV from 
integrated provirus is controlled by cellular oxidation-reduction 
status  and/or  cytokine stimulus.  Oxidants  or  substances 
favoring the production of oxidants, including inflammatory 
cytokines, favor nudear factor (NF)-KB activity and expres- 
sion of HIV (10-12).  Substances that suppress cellular levels 
of oxidants,  including  cysteine, N-acetylcysteine (NAC), 
glutathione, and ascorbic acid, suppress  NF-gB activity and 
HIV expression (13, 14). It should be noted that intracellular 
levels and plasma concentrations of gtutathione decrease in 
patients infected with HIV, and this decrease in glutathione 
is correlated with disease progression in AIDS (15, 16). For 
this reason, therapy with NAC (a glutathione precursor) has 
been suggested for AIDS patients (17,  18). 
The relationship of HIV expression to cellular oxidation- 
reduction status and cytokine stimulus prompted us to inves- 
tigate  the effects of exogenous recombinant TRX/ECEF 
polypeptides on the growth of HIV~a. in the human mac- 
rophages (Me). 
Materials  and Methods 
Recombinant TRX/ECEF Species.  Recombinant TRX/ECEF 
species were generated in Escherichia coli as described (9). The two 
species chosen for evaluation were: (a) the full-length 104 amino 
acid TRX translation product with dithiol reductase activity but 
only weak cytokine activity (9); and (b) a form truncated after amino 
acid 80 with strong cytokine activity but no dithiol reductase ac- 
tivity (9). Endotoxin content of these preparations was <50 pg/ml 
at concentrations used for experiments, as assayed  by the Limulus 
Amebocyte Lysate System (BioWhittaker Inc., Walkersville, MD). 
To  obtain  metabolically  radiolabeled  rTRX  (0.4  x  106 
cpm/mg), TB1 cells transformed with p-MALe vector expressing 
rECEF/TRX-104  were grown to 2  x  10  s cells/ml,  stimulated 
with 0.3 mM isopropylthiogalactoside (Sigma Chemical Co., St. 
Louis, MO),  and  cultured  with  [35S]methionine/cysteine  (250 
uCi/ml of Tran-3SS-Label; ICN Radiochemicals, Irvine CA). The 
fusion protein was purified by amylose resin-maltose binding pro- 
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in RPMI  1640,  as previously done (9). 
Culture of Cells and HIV Infection.  As described (19), human 
Mo were derived by the culture of 107 peripheral blood mono- 
nuclear cells in IMDM (Hyclone Laboratories, Logan, UT) plus 
10% pooled HIV-negative human male serum (Lampire Biological 
Laboratories,  Pipersville,  PA)  in  25-cm  2  tissue  culture  flasks 
(Costar Corp.,  Cambridge, MA).  After 3-5 d,  the nonadherent 
cells were removed. 
The  Mo  (99%  pure  as  determined  by  nonspecific  esterase 
staining) were infected, after a total culture period of 7 d, for 4 h 
with  0.1-1  infectious  units  of HIVB~L (National  Institutes  of 
Health AIDS Research and Reference Reagent Program) per cell. 
After infection, the Mo were washed twice with HBSS (BioWhit- 
taker,  Inc.) and cultured in fresh medium in the presence or ab- 
sence  of rTRX/ECEF  species. Medium was removed on days 2, 
7, and 14 for the determination of HIV p24 antigen. At these time 
points, cells were either harvested for analysis of integrated provirus 
DNA or fed with  fresh medium. 
The OM 10.1 cell line,  a derivative of the HL-60 myelomono- 
cytic leukemia cell line with a single integrated copy of HIV-1L^V 
provirus (20),  was generously provided by Dr.  Salvatore Butera 
(Centers for Disease Control, Atlanta, GA). The cells were main- 
tained in IMDM with 10% fetal bovine serum (Hyclone Laborato- 
ries). 4 d before the experimental treatments, the cells were treated 
with  10 #g/ml of Y-azido-2",3'-dideoxythymidine (AZT; Sigma 
Chemical Co.) to inhibit background expression of HIV. 1 d be- 
fore experimental treatment, the cells were washed and resuspended 
in AZT-free medium. The next day, the cells were seeded  at 106 
in polypropylene culture tubes in 1 ml of medium alone, medium 
plus  100 nM PMA (Sigma Chemical Co.),  or medium plus  100 
U/ml TNF (Cetus Corp., Emeryville, CA), with or without 500 
nM ffRX.  The culture supernatants were harvested at 48 h  for 
the determination  of reverse  transcriptase (RT) activity. 
Parameters of  HIVInfection.  The production of mature HIV was 
determined by quantitative ELISA for the p24 core antigen in cul- 
ture supematants (p24 Core kit; DuPont-NEN Research Products, 
Boston, MA). Control experiments showed that the TRX/ECEF 
reagents did not interfere with the p24 antigen assays. For deter- 
mination of RT activity, virus was precipitated from supernatants 
with 30% polyethylene glycol 8000 (Sigma Chemical Co.) over- 
night at 4~  RT activity was assayed by a nonradioactive, colori- 
metric assay of the precipitate (RT-Assay No. 1468-120; Boehringer 
Mannheim,  Indianapolis,  IN). 
For the determination of integrated proviral DNA, total DNA 
was extracted from Mo by the guanidinium thiocyanate/phenol/ 
chloroform method (21), using Tri Reagent (Molecular Research 
Center, Inc., Cincinnati, OH). 1 #g of isolated DNA was amplified 
by PCR, using the primer pairs SK100 and SK104 (22, 23). These 
primers bracket a highly conserved 290-bp region of HIV-1 gag. 
Quantitation  of HIV-1 DNA was performed using the K4 dele- 
tion mutant, for which the primer pair brackets a 177-bp region, 
as a competitive internal standard (24).  K4 was provided gener- 
ously by Dr. David T. Scadden, New England Deaconess Hospital 
(Boston, MA). Control experiments showed that the internal stan- 
dard and the wild-type gene were amplified at similar rates and 
that no amplified species could be generated from uninfected Mo. 
Determination of rTRX Cleavage by Me.  ILadiolabeled  rTR.X 
was added to washed,  confluent-uninfected or 7-d HIV-infected 
Mo in 24-well tissue culture plates (Costar Corp.), at a concen- 
tration of 60 #g/ml ('~5/~M). After incubation for 1 min or more, 
as described,  the reagent was removed and the cells were rinsed 
once with ice-cold PBS. The Mr  were then lysed by the addition 
of 33 #l/well of SDS-PAGE sample buffer, and lysates of three equiva- 
lent cultures (total volume, 100/A) were analyzed by SDS-PAGE 
in a 15%  reducing gel and autoradiography. 
Results and Discussion 
The Me plays a central role in the pathogenesis  of HIV 
infections.  Transmission  of HIV-1  infection  from  one  in- 
dividual to another appears to be primarily due to monocyto- 
tropic strains that do not induce formation of syncytia (25). 
The chronically infected Mr  also serves as a constant reser- 
voir for the virus (26). For these reasons, we selected the mac- 
rophage  and  the monocytotropic strain  HIV-1B~L  to inves- 
tigate  the  effects of ffRX  and  rECEF. 
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Figure 1.  Regulation  of  HIV  production  in  infected  M0  by 
TRX/ECEF.  Human M0 derived by 5-10-d culture of isolated blood 
monocytes were exposed to 0.1-1 infectious units per ceLl of HIV-1Bat  for 
4 h. After washing, the infected MO were cultured with the indicated re- 
agents. Medium was harvested on days 2, 7, and 14 for analysis of p24 
antigen content.  On days 2 and 7, the replacement medium contained 
fresh TRX/ECEF or NAC. (.4) Representative experiment showing cu- 
mulative p24 antigen production under the different experimental condi- 
tions. Data are pooled from four experiments, with statistical analysis by 
the Wilcoxon signed-rank test. (B) Summary of five experiments (each 
symbol represents a different Me donor) showing the effect of rTRX on 
HIV production within each time segment. The left data point in each 
pair shows p24 antigen produced by untreated cultures; the right data point 
shows production in cultures treated continuously with 500 nM ffRX. 
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medium,  and cultured with test substances as indicated.  At 
optimal  concentrations  (>--0.5/~M),  rTRX  suppressed the 
expression of HIV by up to 100% (n  =  5), as evaluated by p24 
antigen content of the cultures. NAC (30 mM) had a modest 
suppressive effect, that was apparent  at day 7, but not after 
longer incubations.  In contrast,  rECEF induced a 33-92% 
increase in virus expression (n  =  4), that was most clear at 
day 7 (Fig.  1 A). The suppressive effect of ffRX on p24 an- 
tigen production was most prominent in the 7-14-d period 
after infection (Fig.  1 B). No cytopathic effects were observed 
under any of the conditions of treatment,  using phase con- 
trast  microscopy. 
The effects of the rTR`X/ECEF  species  on HIV growth 
were characterized further by quantitative PCR` analysis  for 
the HIV-1 gag gene in cellular DNA extracts. Quantities of 
HIV-1 DNA generally correlated with p24 antigen produc- 
tion. In the example shown (Fig. 2), the amount of detect- 
able HIV  proviral  DNA  in  fiR`X-treated  Me  was  about 
fivefold lower than in rECEF-treated  Me.  In other  experi- 
ments,  in which fiR.X-treated  Me  had  no detectable p24 
antigen, no HIV DNA was detectable at day 14 (control ex- 
periments showed that the threshold of detection in this system 
was  r~104 HIV  DNA  copies).  These  results  show  that 
rTR.X inhibited either the spread of HIV to uninfected cells 
or  superinfection. 
The  suppressive effects of NAC  and rTRX  on HIV ex- 
pression were lost at concentrations below 15 mM and 500 
nM, respectively (Fig. 3). If both substances act by creating 
intracellular  reducing conditions, the ~30,000-fold difference 
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Dose dependence  of regulatory effects, rTRX, rECEF,  and 
NAC were studied for their effects on p24 antigen production at the indi- 
cated concentrations. Data are pooled from three experiments. 
in dose requirements probably reflects the mechanistic differ- 
ences between a stoichiometric reactant  (NAC) and a cata- 
lyst (fiR_X). 
The enhancing  effect of rECEF  on HIV expression was 
detectable at concentrations as low as 50 pM, a sirnilar potency 
to that observed in the assay of eosinophil cytotoxic function 
(9).  In addition,  lower concentrations  of rTRX  (5 and 50 
nM) also enhanced HIV expression, in a manner  similar to 
rECEF-80  (Fig.  3). 
Under the conditions of the experiments described here, 
it  is possible that  the  suppressive effect of rTRX  on HIV 
expression was eroded by ongoing metabolic cleavage of rTRX 
to the truncated ECEF species.  To test for cleavage,  35S-ra- 
diolabeled rTRX was prepared and added to uninfected and 
HIV-l-infected Me. Within  I  min, essentially all cell-asso- 
dated rTRX was detected as a smaller 10-kD species, though 
recombinant maltose-binding protein was unaltered (Fig. 4). 
Analysis also showed that  in the culture supernatant  there 
was a great excess of uncleaved rTRX (data not shown). Fur- 
thermore, the suppressive effect on HIV expression could be 
Figure 2.  Effects of TRX/ECEF  species on quantities of integrated 
HIV provirus.  Under conditions similar to day 14 in Fig. 1 A, the levels 
of integrated DNA were analyzed by a competitive PCR and agarose gel 
(2%) electrophoresis.  The species indicated  by the 290-bp arrow represent 
amplified fragments of the gag  gene from integrated HIV-1B~t provirus. 
The species indicated by the 177-bp arrow represent amplified fragments 
of the titrated internal standard (IS). (~p) The number of IS copies added 
to the PCR reaction. 
Figure 4.  Cleavage of exogenous 
rTR.X by uninfected and HIV-infected 
Me. Human Me derived by 7-d cul- 
ture of  isolated blood monocytes were 
exposed to the 3SS-radiolabeled  ffRX 
reagent, also containing radiolabeled 
maltose-binding protein (MBP, the fu- 
sion protein partner). After 1 min, the 
M~  were  rinsed briefly in  ice-cold 
medium and lysed immediately with 
SDS-PAGE sample buffer. The lysate 
was analyzed by SDS-PAGE  (15% gel) 
and autoradiography. (Lane 1) Com- 
position of the radiolabeled rTRX re- 
agent. (lanes 2 and3) Lysates  of unin- 
fected  and  HIV-infected  Mr  Note 
that the MBP present in the Me ly- 
sate was not  altered.  The  adherent 
rTRX  was  converted  to  a  10-kD 
species. 
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nous rTRX on a regular basis. It is thus likely that the low- 
dose enhancing effect of rTRX on HIV expression resulted 
from metabolic processing of rTRX to ECEF, under condi- 
tions when there was not a great excess of rTRX in the su- 
pernatant (i.e.,  concentrations below 500  nM). 
To determine whether rTRX acts directly on virus parti- 
cles or on the virus-Me interaction, 500 nM rTRX was added 
directly to aliquots of HIV stock for 4 h. The ffRX-treated 
HIV stock was then added directly to the Me. After a 4-h 
period of infection, Me were washed and cultured in fresh 
medium. As measured at 7 and 14 d, there was no difference 
in p24 antigen production between rTRX-treated or untreated 
cultures, indicating that ffRX did not act on the virus directly 
or on the initial virus-cell interactions. 
We wanted to determine whether rTRX could inhibit HIV 
expression at later stages of infection. When the addition of 
rTRX was delayed for 72 h after the infection of Me, there 
was 22-83% inhibition of p24 antigen accumulated at 14 d, 
indicating that rTRX can act at a stage subsequent to the 
initial infection and integration. 
To determine the effects of rTRX in a model of viral latency, 
we used the OM10.1 cell line. The OM10.1 cell contains a 
single integrated HIV provirus that is expressed at very low 
levels but induced by as much as 1,000-fold by various stimuli 
(20).  We found that 500 nM rTRX suppressed both PMA- 
and TNF-induced HIV expression  by 61 and 99%, respec- 
tively,  as evaluated by RT activity at 48 h after induction. 
Since spread of the virus to uninfected cells or superinfection 
was not a significant factor during this brief period, the data 
show that rTRX acts by inhibiting a step in the life cycle 
subsequent to integration of the provirus. Since this experi- 
ment involved a different cell type and HIV-1 strain (HIV- 
1L^v), the results suggest a broad spectrum of cell type and 
viral strain for the suppressive  effect of rTRX. 
Our findings demonstrate that the cleavage of TRX  to 
ECEF is a potential controlling event in the life cycle of HIV, 
and indicate that rTRX deserves evaluation as a potential an- 
tiviral therapeutic agent. 
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